In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant <em>Escherichia coli</em> from Southeastern China

Infect Drug Resist. 2021 Jun 30;14:2499-2507. doi: 10.2147/IDR.S315384. eCollection 2021.

ABSTRACT

PURPOSE: This study aimed to evaluate the in vitro activity of meropenem-vaborbactam (MVB) against a collection of carbapenem-resistant Escherichia coli (CREC) isolates and to compare the activity with other antibiotics with regard to different separation sites, carbapenem-resistant mechanisms, and sequence types (STs).

METHODS: A total of 58 CREC strains were used as the experimental strains from the First Affiliated Hospital of Wenzhou Medical University in southeastern China. The minimum inhibitory concentrations of MVB, ceftazidime-avibactam, and tigecycline against all the experimental strains were determined by the microdilution broth method.

RESULTS: MVB exhibited higher antimicrobial activity (83% susceptibility) than that of other antibiotics, except for colistin and tigecycline. The susceptibility of CREC strains towards MVB varied with regard to carbapenem-resistant mechanisms and STs, especially in Klebsiella pneumoniae carbapenemase (KPC)-positive isolates and ST8 isolates.

CONCLUSION: MVB exhibited considerably high activity against KPC-producing and ST8 CREC isolates. It has the great potential to be an alternative for the treatment of infections caused by CREC after determining the type of carbapenemase, the susceptibility to MVB and/or STs.

PMID:34234477 | PMC:PMC8255899 | DOI:10.2147/IDR.S315384